WO2002007726A3 - Treatment of movement disorders - Google Patents

Treatment of movement disorders Download PDF

Info

Publication number
WO2002007726A3
WO2002007726A3 PCT/GB2001/003260 GB0103260W WO0207726A3 WO 2002007726 A3 WO2002007726 A3 WO 2002007726A3 GB 0103260 W GB0103260 W GB 0103260W WO 0207726 A3 WO0207726 A3 WO 0207726A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
movement disorders
movement
parkison
poverty
Prior art date
Application number
PCT/GB2001/003260
Other languages
French (fr)
Other versions
WO2002007726A8 (en
WO2002007726A2 (en
Inventor
Jonathan Brotchie
Michael Hill
Alan Crossman
Original Assignee
Motac Neuroscience Ltd
Jonathan Brotchie
Michael Hill
Alan Crossman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Motac Neuroscience Ltd, Jonathan Brotchie, Michael Hill, Alan Crossman filed Critical Motac Neuroscience Ltd
Priority to AU2001272649A priority Critical patent/AU2001272649A1/en
Publication of WO2002007726A2 publication Critical patent/WO2002007726A2/en
Publication of WO2002007726A8 publication Critical patent/WO2002007726A8/en
Publication of WO2002007726A3 publication Critical patent/WO2002007726A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

The present invention relates to the use of compounds which inhibit D5-dopamine receptors, such as D5-dopamine receptor antagonists, for the treatment of movement disorders associated with a poverty of movement and more particularly for the treatment of parkinsonism (e.g. Parkison's disease).
PCT/GB2001/003260 2000-07-22 2001-07-20 Treatment of movement disorders WO2002007726A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001272649A AU2001272649A1 (en) 2000-07-22 2001-07-20 Treatment of movement disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0017951.5A GB0017951D0 (en) 2000-07-22 2000-07-22 Treatment of movement disorders
GB0017951.5 2000-07-22

Publications (3)

Publication Number Publication Date
WO2002007726A2 WO2002007726A2 (en) 2002-01-31
WO2002007726A8 WO2002007726A8 (en) 2002-05-02
WO2002007726A3 true WO2002007726A3 (en) 2002-09-06

Family

ID=9896102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003260 WO2002007726A2 (en) 2000-07-22 2001-07-20 Treatment of movement disorders

Country Status (3)

Country Link
AU (1) AU2001272649A1 (en)
GB (1) GB0017951D0 (en)
WO (1) WO2002007726A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324610A2 (en) * 1988-01-15 1989-07-19 Lilly Industries Limited Thieno[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them
US5427942A (en) * 1991-11-13 1995-06-27 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human D5 dopamine recepltor gene and uses
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324610A2 (en) * 1988-01-15 1989-07-19 Lilly Industries Limited Thieno[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them
US5427942A (en) * 1991-11-13 1995-06-27 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human D5 dopamine recepltor gene and uses
US5686573A (en) * 1991-11-13 1997-11-11 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Human D5 dopamine receptor protein
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHO, SEONGEUN ET AL: "Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs", BRAIN RES. (1999), 830(2), 237-245, XP001058991 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, DEN BOER J A ET AL: "Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia.", XP002190774, Database accession no. PREV199698568581 *
DURSUN, SERDAR M. ET AL: "Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions", PSYCHOPHARMACOLOGY (BERLIN) (1996), 128(2), 198-205, XP001059606 *
FICI G J ET AL: "D-1 dopamine receptor activity of anti-Parkinsonian drugs.", LIFE SCIENCES, vol. 60, no. 18, 1997, pages 1597 - 1603, XP001059664, ISSN: 0024-3205 *
GERLACH J. ET AL: "Extrapyramidal symptoms during long-term treatment with antipsychotics: Special focus on clozapine and D1 and D2 dopamine antagonists.", NEUROPSYCHOPHARMACOLOGY, (1996) 14/3 SUPPL. (35S-39S)., XP001058993 *
GRONDIN, RICHARD ET AL: "D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys", NEUROLOGY (1999), 52(4), 771-776, XP001059639 *
KANE J.M. ET AL: "Towards more effective antipsychotic treatment.", BRITISH JOURNAL OF PSYCHIATRY, (1994) 165/NOV. SUPPL. 25 (22-31)., XP001059652 *
LUBLIN, HENRIK ET AL: "Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in Cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity", PSYCHOPHARMACOLOGY (BERLIN) ( 1993 ), 112(2-3), 389-97, XP001059623 *
NEFF N H ET AL: "SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons.", JOURNAL OF NEURAL TRANSMISSION, vol. 107, no. 4, 29 March 2000 (2000-03-29), pages 429 - 443, XP001059435, ISSN: 0300-9564 *
PSYCHOPHARMACOLOGY, vol. 121, no. 3, 1995, pages 317 - 322, ISSN: 0033-3158 *
ZHANG C ET AL: "Neuroregeneration of dopaminergic function by the immunophilin ligand GPI-1046.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 798.2, XP001059679, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
WO2002007726A8 (en) 2002-05-02
AU2001272649A1 (en) 2002-02-05
GB0017951D0 (en) 2000-09-13
WO2002007726A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
MXPA03009644A (en) 1 substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists).
WO2001072291A3 (en) Treatment of movement disorders with metabotropic glutamate receptor antagonist
PT1235787E (en) BETA2 ADRENERGIC AGONISTIC RECEPTORS
WO2004018386A3 (en) Acetophenone potentiators of metabotropic glutamate receptors
HK1072052A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
PL369026A1 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
WO2007061763A3 (en) Indole orexin receptor antagonists
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
EP1223938A4 (en) TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/$g(a) 2? ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS
WO2003048120A3 (en) 2-aryl pyrrologpyrimidines for a1 and a3 receptors
MXPA03009185A (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson s disease.
EP2298298A3 (en) Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
WO2007019234A3 (en) Aminoethane sulfonamide orexin receptor antagonists
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
HK1038925A1 (en) Crf receptor antagonists and methods relating thereto crf
CA2338066A1 (en) Treatment of dyskinesia
AU2001263130A1 (en) Bicyclic cyclohexylamines and their use as nmda receptor antagonists
WO1999029308A3 (en) Method for combating obesity
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
AU2002343523A1 (en) Methods of using 279, a human g protein-coupled receptor
WO2002007726A3 (en) Treatment of movement disorders
EP1545508A4 (en) 3,6-disubstituted azabicyclo ¬3.1.0 hexane derivatives useful as muscarinic receptor antagonist
WO2000006082A3 (en) Treatment of anxiety disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP